[The dose-response relationship in the use of hexabrix in angiography]

The authors present the results of a clinical trial of Hexabrix, a new radiopaque low osmolar agent, to be used in visceral catheterization translumbar angiography. Hexabrix was shown to reduce the frequency of side-effects by 40% as compared to triiodinated agents. The new agent causes no marked reactions in intraarterial administration even at a dose over 2 ml/kg. Hexabrix is an agent of choice to be used for patients at risk of angiographic investigation (allergy, advanced age, a severe general condition).